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CASE REPORT

Fatal COVID-19 infection in a patient with long-chain
3-hydroxyacyl-CoA dehydrogenase deficiency: A case report
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Abstract
Long-chain fatty-acyl CoA dehydrogenase deficiency (LCHADD) is an inborn
error of long chain fatty acid oxidation with various features including
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hypoketotic hypoglycemia, recurrent rhabdomyolysis, pigmentary retinopathy,
peripheral neuropathy, cardiomyopathy, and arrhythmias. Various stresses
trigger metabolic decompensation. Coronavirus disease 2019 (COVID-19) is a
pandemic caused by the RNA virus SARS-CoV-2 with diverse presentations
ranging from respiratory symptoms to myocarditis. We report a case of a
patient with LCHADD who initially presented with typical metabolic decompensation symptoms including nausea, vomiting, and rhabdomyolysis in addition to mild cough, and was found to have COVID-19. She developed acute
respiratory failure and refractory hypotension from severe cardiomyopathy
which progressed to multiple organ failure and death. Our case illustrates the
need for close monitoring of cardiac function in patients with a long-chain
fatty acid oxidation disorder.

Communicating Editor: Piero Rinaldo
KEYWORDS
cardiomyopathy, COVID-19, fatty acid oxidation disorder, LCHAD, long-chain 3-hydroxyacyl-CoA
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1 | INTRODUCTION
Long-chain fatty-acyl CoA dehydrogenase deficiency
(LCHADD, OMIM #609016) is an inborn error of metabolism caused by pathogenic variants in HADHA.1 Mitochondrial trifunctional protein (MTP) consists of four
alpha subunits encoded by HADHA and four beta subunits encoded by HADHB.2 MTP catalyzes three steps in
long chain fatty acid oxidation including long-chain
3-hydroxyacyl-CoA dehydrogenase (LCHAD), long-chain

enoyl-CoA hydratase (LCEH), and long-chain 3-ketoacylCoA thiolase (LCKAT).3,4 Alpha subunits possess
LCHAD and LCEH activities, while beta subunits have
LCKAT activity.5 Pathogenic variants in HADHA disrupting LCHAD activity cause LCHADD,6 while those in
HADHA and HADHB causing loss of function in other
enzymatic activities of MTP leads to trifunctional protein
deficiency (mTPD, OMIM #609015).7-9 Clinical characteristics of patients with LCHADD and mTPD are similar to
other long chain fatty acid oxidation disorders, including
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hypoketotic hypoglycemia, recurrent rhabdomyolysis,
however,
cardiomyopathy,
and
arrhythmias10-15;
LCHADD and mTPD can cause peripheral neuropathy
and pigmentary retinopathy that are irreversible.12-17 Age
of onset and severity of symptoms of LCHADD and
mTPD are highly variable.12 Physiologic stress, including
illness, and inappropriate diet cause acute metabolic
decompensation and may lead to death.18 Dietary treatment with long chain fatty acid restriction and medium
chain triglyceride (MCT) supplementation are the mainstays of LCHADD treatment and prevention of
complications.19
Coronavirus disease 2019 (COVID-19) is an emerging
disease caused by a novel coronavirus, namely severe acute
respiratory syndrome coronavirus 2 (SARS-CoV-2).20
COVID-19 was declared a pandemic on 11 March 2020 by
the World Health Organization.21 The most common presenting symptoms of COVID-19 include fever, fatigue, dry
cough, myalgia, dyspnea, and loss of olfactory sensation.22,23 Headache, dizziness, abdominal pain, diarrhea,
nausea, and vomiting are less common presenting symptoms.22,23 Acute respiratory distress syndrome and sepsis
are major complications associated with death in COVID19 patients.24 Cardiovascular involvement, including cardiomyopathy, ventricular arrhythmia, and hemodynamic
instability have been reported in COVID-19 patients without underlying cardiovascular disease.25,26
Infections are common triggers of metabolic decompensation in patients with inborn errors of metabolism,
leading to a higher risk for severe complications. It is
unknown whether individuals with inborn errors of
metabolism are at greater risk of serious illness due to
COVID-19. Here we report a patient with LCHADD and
COVID-19 who developed severe cardiomyopathy and
multiple organ system failure leading to death.

2 | CASE REPORT
The patient was a 23-year-old Caucasian female who
presented to a local hospital due to chest pain and nausea. Three days prior to admission, she developed an
intermittent dry cough. One day prior to admission, she
developed chest and epigastric pain as well as nausea and
vomiting similar to her prior episodes of metabolic
decompensation and rhabdomyolysis. She had a decrease
in oral intake. At the local hospital she was found to have
an elevated creatine kinase level of 15 380 units/mL (normal range 30-200 units/L) along with an elevated troponin
T level of 0.23 ng/mL (normal range 0.00-0.03 ng/mL),
and a creatinine of 0.49 mg/dL (normal range 0.601.10 mg/dL). Her vital signs were normal and she did not
require oxygen supplementation. She was transported to
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Synposis
Patients with inborn errors of metabolism
should be considered a vulnerable population
for COVID-19, given the risks of severe
complications.

our hospital for management. On arrival, she tested positive for COVID-19 by nasopharyngeal swab real-time
RT-PCR assay and was transferred to a COVID-19
isolation unit.
Her past medical history was notable for LCHADD
which was diagnosed at 4 months of age when she presented with apnea, lactic acidosis, and hypoglycemia. Her
mother's pregnancy had been complicated by acute fatty
liver of pregnancy. Genetic testing revealed compound
heterozygosity for a paternally inherited c.274_278del
(p.Ser92fs) variant and a maternally inherited c.1528G>C
(p.Glu510Gln) variant. Lactic acidosis and hypoglycemia
in infancy resolved after dietary treatment for LCHADD
was instituted. She had multiple complications of
LCHADD including progressive retinopathy with severe
visual impairment and peripheral neuropathy. During
pregnancy at age 21, she was diagnosed with long QT
interval with self-limited torsade de pointes, and was
treated with propranolol. Her last echocardiogram
6 weeks prior to this hospitalization showed a normal left
ventricular ejection fraction (LVEF) of 62% and normal
right ventricular function. Regarding LCHADD management, she was prescribed 44 g/d of medium-chain triglyceride and L-carnitine supplementation with a low-fat
dietary restriction. Intermittent non-compliance had led
to multiple episodes of metabolic decompensation and
rhabdomyolysis.
On arrival to our hospital, she continued to experience nausea, vomiting, and intermittent dry cough.
Telemetry monitoring was initiated. She was started on
deep vein thrombosis prophylaxis with 40 mg of subcutaneous enoxaparin daily. Her electrocardiogram was
notable only for a prolonged QT interval of 526 ms
which was unchanged from prior studies. She initially
received an intravenous fluid bolus with 1 L of Ringer's
lactate solution and was transitioned to continuous
intravenous fluids containing 10% dextrose at 1.5 times
maintenance rate (150 mL/h) for a glucose infusion rate
(GIR) of 3.4 mg/kg/min. Her intake of MCTs was
increased to 70 g/day with continuation of L-carnitine
supplement and dietary fat intake restriction. She was
instructed to drink Ensure Clear for additional calories
and protein. However, she was not able to achieve her
nutritional goal due to nausea, leading to further elevation in her creatine kinase to 40 600 units/L on day 4 of
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admission. She developed acute kidney injury with creatinine rising from 0.51 mg/dL on admission to
2.25 mg/dL despite the increase of intravenous fluids
containing 10% dextrose to a GIR of 4.2 mg/kg/min. She
began to show signs of volume overload with peripheral
edema. The patient did not tolerate placement of a nasogastric tube for feeding. A PICC line was placed on day
2 of admission and the patient was started on parenteral
nutrition supplementation on day 5 of admission with
dextrose 480 g/d and protein 1.5 g/kg/d. By day 11 of
admission, her creatine kinase and serum creatinine
improved to 1669 units/L and 0.72 mg/dL, respectively.
She continued to have an intermittent cough, but had
no shortness of breath or requirement for supplemental
oxygen. Her vital signs were stable with the exception of
an intermittent fever, and review of her telemetry
showed no events.
On day 11 of admission, she developed acute onset
of oxygen desaturation. On arrival to the bedside, nursing noted that the patient was confused and intermittently voicing difficult breathing, in visible respiratory
distress, and ashen with cold extremities. She was afebrile. They were unable to obtain reliable oxygen saturation or blood pressure. The rapid response team was
called. Anesthesia performed rapid sequence intubation
with video-assisted laryngoscopy. She was placed on
pressure-regulated volume control mechanical ventilation. Her arterial blood gas after intubation revealed a
pH 7.23, pCO2 33 mm Hg, pO2 262 mm Hg, base excess
−13. Her lactate was 12.8 mmol/L (reference range
0.7-2.0 mmol/L). N-terminal pro-brain natriuretic
peptide was 902 pg/mL (normal range < 300 pg/mL),
compared to a level of 1205 pg/mL on day 6 of admission. Fibrinogen was 816 mg/dL (normal range
170-400 mg/dL). D-dimer was 1467 ng/mL (normal
range < 499 ng/mL). Troponin I was 0.08 ng/mL
(0.00-0.03 ng/mL). No blood gas was obtained prior to
intubation. She was profoundly hypotensive after intubation with systolic blood pressures of 30-40 mm
Hg. She was started on pressor support with a norepinephrine drip and transferred to the ICU.
On arrival to the ICU, bedside cardiac and lower
extremity ultrasound revealed decreased right ventricular
function and suspected lower extremity venous clots. She
was given 200 mg of alteplase empirically due to concern
for pulmonary embolism causing obstructive shock and
hypoxemic respiratory failure. She was started on empiric
broad spectrum antibiotics with linezolid, cefepime, and
micafungin. Despite these interventions, the patient
required rapidly increasing levels of pressor support with
the addition of vasopressin and epinephrine. A few hours
after transfer to the ICU, venoarterial extracorporeal
membrane oxygenation (VA-ECMO) was initiated with
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cannulas in the right common femoral vein and left common femoral artery. Despite multiple attempts, the cardiothoracic surgery team was unable to visualize or
access the left superficial femoral artery for placement of
a distal perfusion catheter.
A computed tomography (CT) of the chest 18 hours
after alteplase did not show a PE but was notable for
small bilateral pleural effusions with right lower lobe and
partial left lower lobe collapse, scattered ground glass
opacities, and septal line thickening. Transthoracic echocardiogram revealed moderate global left ventricular dysfunction with an LVEF of 34% and moderate right
ventricular dilatation with severe right ventricular
hypokinesis. Review of her telemetry showed no
evidence of arrhythmia or ischemia during the peridecompensation period. Urinalysis revealed leukocyte
esterase 3+, protein 2+, nitrite negative, bacteria 3+,
greater than 50 white blood cells per high power field,
and greater than 50 red blood cells per high power field.
Urine culture was positive for Escherichia coli. Blood cultures grew Enterobacter cloacae. The source of her bacteremia was thought to be related either to her PICC line or
to gut translocation. Her PICC line was removed and parenteral nutrition was stopped. She was diagnosed with
combined cardiogenic and septic shock. She did not
receive systemic corticosteroids.
After ECMO cannulation, she had undetectable dorsalis pedis pulses by palpation and arterial Doppler ultrasound. Vascular surgery believed that the combination of
severe hypotension and ECMO placement had led to
poor perfusion of her lower extremities, but no surgical
intervention was immediately indicated. On day 12 of
admission, liver function studies showed newly elevated
transaminases with an alanine aminotransferase of
800 units/L (normal range 7-45 units/L) and an aspartate
aminotransferase of 1175 units/L (normal range
10-45 units/L). Her ammonia level was normal at
48 μmol/L. Elevated transaminases were attributed to
ischemic liver injury. Despite continuing to be critically
ill on ventilator and pressor support, her condition stabilized for a few days after ECMO cannulation. Notably,
her kidney function remained normal with good urine
output and her creatinine kinase levels remained stable
at 3000-4000 units/L despite the cessation of parenteral
nutrition. A repeat echocardiogram on day 13 demonstrated RV dilation with normalization of RV systolic
function and improvement of LVEF to 41%. On day
15, she had increased mottling of the left foot and therefore, she underwent ECMO revision. Post-operatively,
she developed worsening hypotension and lactic acidosis.
A CT of the chest, abdomen, and pelvis on day 16 revealed ischemic nonocclusive enteritis involving the
majority of the small bowel and ascending colon with
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suspicion for mucosal breach in the right lateral wall of
the descending colon. Emphysematous esophagitis and
gastritis were also suspected on the CT. Despite aggressive measures, she developed sustained refractory hypotension leading to a decision to withdraw medical
support. She died on day 17 of admission. An autopsy
was not performed due to COVID-19.

3 | DISCUSSION
We report a patient with LCHADD admitted due to
COVID-19 and rhabdomyolysis. She initially presented
with mild upper respiratory tract symptoms and did not
require oxygen supplementation. Metabolic decompensation led to rhabdomyolysis and acute kidney injury.
Improvement in metabolic status and renal function were
observed over the first week of hospitalization with adequate nutritional supplementation. However, she suddenly developed acute respiratory failure and acute
cardiomyopathy, leading to death despite maximal
support.
Cardiomyopathy is a major complication of long-chain
fatty acid oxidation disorders including LCHADD and
mTPD.10-13 Patients with LCHADD and mTPD can
develop hypertrophic cardiomyopathy, dilated cardiomyopathy, and arrhythmias.27,28 The pathophysiology of cardiac complications in LCHADD is still unclear. Proposed
mechanisms include the accumulation of toxic long-chain
acylcarnitines or deficiency of energy substrate.28,29 Severe,
acute cardiomyopathy with rapid reduction in LVEF has
been reported in an LCHADD patient with an acute metabolic crisis, exacerbated by dietary noncompliance and
infection,27 similar to our patient whose echocardiogram
was normal prior to this admission.
COVID-19 is an emerging infectious disease that
became a global public health emergency and pandemic.21 Although COVID-19 was initially thought to primarily involve the respiratory tract, recent studies have
revealed extrapulmonary manifestations. Cardiac
involvement has been reported in multiple cases and cardiomyopathy is the most common cardiac complication.22-25,30 Another report described a patient who
presented with cardiomyopathy with minimal respiratory
symptoms, similar to our patient.25 Recent studies revealed that approximately one-third of the patients with
severe COVID-19 requiring intensive care exhibited cardiomyopathy.31 Those patients who have underlying cardiac disease are at risk of severe COVID-19.30,32 These
studies illustrate the strong association of COVID-19 with
cardiac involvement. Several mechanisms leading to
myocardial injury are proposed, including myocardial
injury caused by viral infection, systemic inflammation
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leading to cytokine storm, altered myocardial metabolic
demand, abnormal coagulation leading to thromboembolism, adverse effects from treatment, and electrolyte
imbalance.30 In our patient, one possibility is that
COVID-19 and systemic inflammation led to increased
metabolic demand and eventually metabolic crisis which
caused LCHADD-related cardiomyocyte injury in addition to viral myocarditis. We hypothesize that this vicious
cycle eventually caused cardiomyopathy and cardiac dysfunction. Coagulation disorders are known to be relatively common complications of COVID-19.33 A
hypercoagulable state leading to thrombi formation that
could not be detected by CT or were quickly cleared by
fibrinolytics or anticoagulants is another possible cause
of the acute deterioration seen in our patient. Autopsy
with analysis of cardiac tissue could have provided more
information and possible mechanisms leading to cardiomyopathy. However, due to COVID-19 restrictions,
autopsy was not performed.
In conclusion, we report a case of LCHADD patient
with fatal COVID-19. This case illustrates the need for
close monitoring of cardiac function in patients with fatty
acid oxidation defects who develop COVID-19. Patients
with inborn errors of metabolism should be considered a
vulnerable population for COVID-19, given the risks of
developing metabolic decompensation and severe
complications.
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